



An official website of the United States government

[Here's how you know](#)

Log in

MeSH



"Chloroquine"



Summary 20 per page

Search results

Items: 1 to 20 of 32

- [Chloroquine](#)
 1. The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.

- [chloroquine diphosphate \[Supplementary Concept\]](#)
 2. Date introduced: April 23, 1980

- [PfCRT protein, Plasmodium falciparum \[Supplementary Concept\]](#)
 3. a digestive vacuole protein isolated from Plasmodium falciparum; a point mutation confers **chloroquine** resistance
Date introduced: December 5, 2000

- [ferriprotoporphyrin IX-chloroquine complex \[Supplementary Concept\]](#)

4. more effective than **chloroquine**

Date introduced: July 13, 1991

[chloroquine receptor \[Supplementary Concept\]](#)

5. Date introduced: July 22, 1981

[Ro 11 \[Supplementary Concept\]](#)

6. drug combination of **chloroquine** & a tiapamil analog calcium channel blocker N-(3,4-dimethoxyphenyl-N-methyl-2-naphthyl)-m-dithiane-2-propylamine; used in treatment of **chloroquine**-resistant malaria in monkeys
Date introduced: March 14, 1993

[aminobenzoic acid, calcium pantothenate, chloroquine, quinacrine, pyridoxine drug combination \[Supplementary Concept\]](#)

7. Date introduced: January 8, 1987

[desethylchloroquine \[Supplementary Concept\]](#)

8. metabolite of **chloroquine**
Date introduced: January 1, 1974

[Quinacrine](#)

9. An acridine derivative formerly widely used as an antimalarial but superseded by **chloroquine** in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
Year introduced: CHINACRIN was see QUINACRINE 1977-1993

[chloroquine-N-oxide \[Supplementary Concept\]](#)

10. Date introduced: December 29, 2013

[malyngolide dimer \[Supplementary Concept\]](#)

11. from cyanobacterium *Lyngbya majuscula*; showed moderate in vitro antimalarial activity against **chloroquine**-resistant *Plasmodium falciparum*

and toxicity against H-460 human lung cell lines; structure in first source

Date introduced: June 2, 2010

[Crt-o protein, Plasmodium vivax \[Supplementary Concept\]](#)

12. has been sequenced

Date introduced: June 30, 2009

[1,3-dihydro-1-\(1-\(\(4-\(6-phenyl-1H-imidazo\(4,5-g\)quinoxalin-7-yl\)phenyl\)methyl\)-4-piperidinyl\)-2H-benzimidazol-2-one \[Supplementary Concept\]](#)

inhibits both Akt1 and Akt1; has a synergistic effect against cancer when combined with **chloroquine**; structure in first source

Date introduced: November 2, 2008

[palladium-chloroquine \[Supplementary Concept\]](#)

14. structure in first source

Date introduced: April 12, 2006

[4-\(5-trifluoromethyl-1H-pyrazol-1-yl\)-chloroquine \[Supplementary Concept\]](#)

structure in first source

Date introduced: March 23, 2006

[BG 958 \[Supplementary Concept\]](#)

16. reverses in vitro **chloroquine** resistance

Date introduced: January 16, 2005

[neutral aminopeptidase, Plasmodium berghei \[Supplementary Concept\]](#)

17. **chloroquine**-induced redistribution of enzyme may be the cause of hemoglobin accumulation in endocytic vesicles of malaria parasites

Date introduced: March 24, 2003

[CG1 protein, Plasmodium falciparum \[Supplementary Concept\]](#)

18. isolated from *Plasmodium falciparum*; may be involved in **chloroquine** resistance; amino acid sequence in first source
Date introduced: December 26, 1997

[CG2 protein, *Plasmodium falciparum* \[Supplementary Concept\]](#)

19. 330-kDa; polymorphisms linked to **chloroquine**-resistance; isolated from *Plasmodium falciparum*
Date introduced: December 26, 1997

[chloroquine\(triphenylphosphine\)gold\(I\) \[Supplementary Concept\]](#)

20. structure in first source
Date introduced: July 11, 1997